Silodosin 4mg versus tamsulosin 0.2mg once daily; randomized crossover study

Silodosin 4mg versus tamsulosin 0.2mg once daily; randomized crossover study - Silodosin 4mg versus tamsulosin 0.2mg once daily; randomized crossover study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004918

Enrollment

Registered

2011-01-21

Start date

2011-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign prostate hyperplasia

Interventions

Silodosin preceding group (30 cases): 4 weeks of once a day administration of silodosin at 4 mg, followed by 4 weeks of once a day administration of tamsulosin at 0.2 mg. Tamsulosin preceding group (3

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: IPSS>=8, QOL score>=3, Prostate volume (by transabdominal or transrectal ultrasound) >=20ml

Exclusion criteria

Exclusion criteria: Patients who took alfa 1 blocker within 28 days; patients who were taking phosphodiesterase 5 inhibitor, 5 alfa reductase inhibitor and antiandrogen; patients with severe renal disfunction (eGFR<30ml/min/1.73m2); or patients who were judged to be inappropirate by physicians.

Design outcomes

Primary

Measure	Time frame
International prostate symptom score (IPSS), overactive bladder symptom score, quality of life (QOL) score	—

Secondary

Measure	Time frame
Uroflowmetry, blood pressure, male sexual function	—

Countries

Japan

Contacts

Public ContactAkira NORO

Saitama Red Cross Hospital Department of Urology

srch.uro@mopera.ne.jp+81-48-852-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026